Printer Friendly

CEL-SCI CORPORATION SHARES NOW TRADE IN NASDAQ NATIONAL MARKET

 CEL-SCI CORPORATION SHARES NOW TRADE IN NASDAQ NATIONAL MARKET
 ALEXANDRIA, Va., Feb. 10 /PRNewswire/ -- The common stock of CEL-SCI Corporation (NASDAQ-NMS: CELI) had its secondary public offering on Feb. 7 and began trading today in the NASDAQ National Market (NMS), Maximilian de Clara, president and chief executive officer announced. The secondary offering raised just under $14 million before expenses.
 CEL-SCI Corporation is a biotechnology company developing drugs for the treatment of cancer and the treatment/prevention of AIDS.
 De Clara noted that CEL-SCI Corporation's entry into the NASDAQ National Market provides brokers and others with immediate access to the best bid and asked prices and other information about the company's shares throughout the trading day. Those prices are available over more than 190,000 electronic terminals in brokers' offices throughout the United States and the free world. Trading data are also distributed widely through wire services for selective dissemination by newspapers and radio and television stations.
 -0- 2/10/92
 /CONTACT: Matt Haines, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI Corporation/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: MTC SU:


MH -- DC006 -- 8153 02/10/92 09:27 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:190
Previous Article:HOECHST AND HORSEHEAD INDUSTRIES MERGE WORLDWIDE GRAPHITE OPERATIONS
Next Article:NORTHEAST FEDERAL CORPORATION ANNOUNCES REVISED UNDERSTANDING WITH REPRESENTATIVES OF THE FEDERAL DEPOSIT INSURANCE CORPORATION
Topics:


Related Articles
CEL-SCI REQUESTS THAT UNITS CEASE TRADING ON NASDAQ SYSTEMS
CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
CEL-SCI CORPORATION TECHNOLOGY PROTECTED BY NEW JAPANESE PATENT
CEL-SCI CORPORATION BEGINS ADVANCED CLINICAL STUDY WITH HGP-30 AIDS VACCINE
CEL-SCI GETS NEW STOCK SYMBOL FOR 30 DAYS
CEL-SCI ENTERS INTO AGREEMENT TO GAIN 100% OWNERSHIP OF AIDS TECHNOLOGY
CEL-SCI CORPORATION EXTENDS EXPIRATION DATE OF WARRANTS TRADING AS 'CELIW' UNTIL FEB. 6, 1997
CEL-SCI RAISED $1.45 MILLION IN MARCH
CEL-SCI Raises $5.0 Million
CEL-SCI Corporation Extends Warrant Date

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters